ConductScience.org, home

Paper28933751

Rapid Mechanistic Evaluation and Parameter Estimation of Putative Inhibitors in a Single-Step Progress-Curve Analysis: The Case of Horse Butyrylcholinesterase.

Stojan J. Molecules, 2017. Cited by 9 papers, by iCite.

Cite this record

ConductScience Library. Rapid Mechanistic Evaluation and Parameter Estimation of Putative Inhibitors in a Single-Step Progress-Curve Analysis: The Case of Horse Butyrylcholinesterase. Papers, record 28933751. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/28933751

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Rapid Mechanistic Evaluation and Parameter Estimation of Putative Inhibitors in a Single-Step Progress-Curve Analysis: The Case of Horse Butyrylcholinesterase.
PubMed
Journal
Molecules
PubMed
Year
2017
PubMed
Publication types
Evaluation Study, Journal Article
PubMed
Citations, by iCite
9
iCite
Relative citation ratio, by iCite
0.51
iCite
Revised in PubMed
2019-12-10
PubMed

Authors1

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Stojan JJure

Source PubMed

Download CSV of authors

Topics9

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
ButyrylcholinesteraseMajor topic
ButyrylthiocholineMajor topic
Cholinesterase InhibitorsMajor topic
Animals
Horses
Kinetics
Ligands
Models, Biological
Sodium Fluoride

Source PubMed

Download CSV of topics

References26

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
121091433X-ray crystallographic snapshots of reaction intermediates in the G117H mutant of human butyrylcholinesterase, a nerve agent target engineered into a catalytic bioscavenger.Biochem J2011https://conductscience.org/library/papers/21091433PubMed
25963443Chemical structure and function of the active center of acetylcholinesterase.Biochemistry1966https://conductscience.org/library/papers/5963443PubMed
315304240Cholinesterase inhibitors: new roles and therapeutic alternatives.Pharmacol Res2004https://conductscience.org/library/papers/15304240PubMed
425226236Discovery, biological evaluation, and crystal structure of a novel nanomolar selective butyrylcholinesterase inhibitor.J Med Chem2014https://conductscience.org/library/papers/25226236PubMed
528000737Development of an in-vivo active reversible butyrylcholinesterase inhibitor.Sci Rep2016https://conductscience.org/library/papers/28000737PubMed
64000107The slow rate of inhibition of acetylcholinesterase by fluoride.Mol Pharmacol1985https://conductscience.org/library/papers/4000107PubMed
715030487Inhibition of Drosophila melanogaster acetylcholinesterase by high concentrations of substrate.Eur J Biochem2004https://conductscience.org/library/papers/15030487PubMed
8891Acetylcholinesterase.Adv Enzymol Relat Areas Mol Biol1975https://conductscience.org/library/papers/891PubMed
911856351Concentration-dependent reversible activation-inhibition of human butyrylcholinesterase by tetraethylammonium ion.Eur J Biochem2002https://conductscience.org/library/papers/11856351PubMed
1012941576Treatment of Alzheimer's disease: current status and new perspectives.Lancet Neurol2003https://conductscience.org/library/papers/12941576PubMed
1119627979Application of the Van Slyke-Cullen irreversible mechanism in the analysis of enzymatic progress curves.Anal Biochem2009https://conductscience.org/library/papers/19627979PubMed
1227858711Cholinesterase Inhibitor Therapy in Alzheimer's Disease: The Limits and Tolerability of Irreversible CNS-Selective Acetylcholinesterase Inhibition in Primates.J Alzheimers Dis2017https://conductscience.org/library/papers/27858711PubMed
1322630075The integrated Michaelis-Menten rate equation: déjà vu or vu jàdé?J Enzyme Inhib Med Chem2013https://conductscience.org/library/papers/22630075PubMed
143982389Butyrylcholinesterase: inhibition by arsenite, fluoride, and other ligands, cooperativity in binding.Mol Pharmacol1985https://conductscience.org/library/papers/3982389PubMed
159890890Substrate binding to the peripheral site of acetylcholinesterase initiates enzymatic catalysis. Substrate inhibition arises as a secondary effect.Biochemistry1999https://conductscience.org/library/papers/9890890PubMed
1626632651Novel Tacrine-Benzofuran Hybrids as Potent Multitarget-Directed Ligands for the Treatment of Alzheimer's Disease: Design, Synthesis, Biological Evaluation, and X-ray Crystallography.J Med Chem2016https://conductscience.org/library/papers/26632651PubMed
171001690Design and analysis of progress curves in enzyme kinetics.Biochem Soc Trans1976https://conductscience.org/library/papers/1001690PubMed
1811259830Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings.Adv Drug Deliv Rev2001https://conductscience.org/library/papers/11259830PubMed
198415649Quaternary ligand binding to aromatic residues in the active-site gorge of acetylcholinesterase.Proc Natl Acad Sci U S A1993https://conductscience.org/library/papers/8415649PubMed
2023279886The significance of low substrate concentration measurements for mechanistic interpretation in cholinesterases.Chem Biol Interact2013https://conductscience.org/library/papers/23279886PubMed

See all 26 referencesDownload CSV of references

Cited by4

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 9 citations.

PMIDTitleJournalYearIn PapersSource
35563466Kinetic Modeling of Time-Dependent Enzyme Inhibition by Pre-Steady-State Analysis of Progress Curves: The Case Study of the Anti-Alzheimer's Drug Galantamine.Int J Mol Sci2022https://conductscience.org/library/papers/35563466PubMed
35209091The Removal of Time-Concentration Data Points from Progress Curves Improves the Determination of Km: The Example of Paraoxonase 1.Molecules2022https://conductscience.org/library/papers/35209091PubMed
31914836Development of potent reversible selective inhibitors of butyrylcholinesterase as fluorescent probes.J Enzyme Inhib Med Chem2020https://conductscience.org/library/papers/31914836PubMed
31426402New Sesquiterpenoids from the Fermented Broth of Termitomyces albuminosus and their Anti-Acetylcholinesterase Activity.Molecules2019https://conductscience.org/library/papers/31426402PubMed

Download CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
BCHE590PubTator's text mininghttps://conductscience.org/library/genes/590

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/28933751

GET https://conductscience.org/api/papers/v1/28933751/references?page=2